Novo Nordisk announced results from INFORM survey on semaglutide

Novo Nordisk (NVO) “announced results from the US-based INFORM survey of people taking semaglutide for weight management, Wegovy, at the European Association for the Study of Diabetes 2025, Vienna, Austria. The INFORM survey revealed that individuals experienced a substantial drop in food noise after starting Wegovy(R) treatment, alongside notable improvements in their mental well-being and lifestyle. Food noise – unwanted and intrusive thoughts about food – can affect the mental well-being, quality of life and weight loss efforts of those living with overweight or obesity. On Wegovy treatment, the survey showed a decline of 46% in the number of people experiencing constant thoughts about food throughout the day. The proportion of participants who reported that food noise had a negative effect on their lives was 60% before starting treatment, which dropped to 20% for respondents on Wegovy(R) treatment. Around two-thirds of respondents reported that their mental health improved since starting Wegovy treatment.1 Substantial majorities also reported developing a healthier lifestyle (76%) and healthier habits Around 8 in 10 (83%) of individuals in the study were satisfied with their Wegovy(R) treatment.”